ORPHAGEN PARTNER, JAPAN TOBACCO, INITIATES A PHASE I CLINICAL TRIAL OF A NOVEL SMALL MOLECULE THERAPEUTIC FOR AUTOIMMUNE AND ALLERGIC DISEASES

...

Orphagen Pharmaceuticals Presents Pharmacology of ROR-beta Antagonists at the Keystone Symposium on Nuclear Receptors

...

Orphagen Pharmaceuticals Awarded Federal Funding to Investigate a Novel Drug Discovery Target for Sickle Cell Disease

...

Orphagen Pharmaceuticals Awarded $224,954 to Investigate an Orphan Nuclear Receptor as Novel Drug Discovery Target for Cancer Immunotherapy

...

Recent News

Robin Jackman joins the Orphagen Board of Directors

Orphagen Pharmaceuticals announced today that Robin Jackman, CEO of Leading BioSciences, has been appointed to the Board of Directors. “Robin brings crucial experience to our Board in finance and fund-raising. This comes on top of his excellent record in guiding two...

News Archives